RE:RE:RE:Another hypothetical The way I've seen MDGL data talked about is as a derisking on the safety side of the equation. The stock really has responded. Back to $1.6 billion valuation. Akero is following them up, some others not so much. Maybe some anticipation they can hit their numbers in the registrational trial.
SPCEO1 wrote: MDGL's response to the less important results (the key trial has not reported out yet) was fascinating. Big response to them in pre-market, a sell-off pretty quickly in real trading hours and then another big jump in the days thereafter. Since MDGL is much better followed by analysts, it shows that does not even guarantee a logical response, at least initially. But at least MDGL does have analysts from sizable firms covering the stock - that will save the day in the end. At the moment, THTX only has the hope of such better analyst coverage.
archeo753 wrote: MDGL had a very muted response to their latest PH 3 results in the first 2 days after the press release. Since then, however, they have had a very impressive multi day share price gain which hasn't yet run out of steam. Hard to predict what could happen to TH with good news but might be worth holding on a little longer to maximize gains.
SS1316 wrote: TH seems to always sell off on any positive SP movement, seems as though investors are looking to cash in on their patients even if they're just scalping.
'Hypothetical scenario' if the positive news that we are all imagining for the 1a trial comes through to break TH's deafening scilence annnd the market somehow notices it annnd has a positive response, let's just say a 55% gain over a couple trading days, how quick does it sell off?
Only a hypothetical question, I'm defiantly not over leveraged here.